Blog
RSS FeedPosted by Michael Wonder on 04 Jun 2025
MHRA approves aumolertinib to treat non-small cell lung cancer
3 June 2025 - The MHRA has approved aumolertinib (Aumseqa) for adult patients with non-small cell lung cancer. ...
Posted by Michael Wonder on 18 May 2025
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
16 May 2025 - The MHRA has today approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis. ...
Posted by Michael Wonder on 17 May 2025
MHRA approves vaccine to protect against pneumococcal infections such as pneumonia and meningitis
15 May 2025 - The MHRA has today approved a vaccine (Capvaxive) for people aged 18 years and older to help ...
Posted by Michael Wonder on 14 May 2025
MHRA approves first UK treatment for congenital thrombotic thrombocytopenic purpura
12 May 2025 - The MHRA has today approved rADAMTS13 (Adzynma), the first UK treatment to treat congenital thrombotic thrombocytopenic purpura ...
Posted by Michael Wonder on 12 May 2025
Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near zero global warming potential
11 May 2025 - Trixeo Aerosphere, AstraZeneca’s fixed-dosed triple-combination therapy for COPD, is the Company’s first medicine to transition to ...
Posted by Michael Wonder on 19 Jan 2025
Aprocitentan approved to treat adults with hypertension whose blood pressure cannot be controlled by other medications
17 January 2025 - The MHRA has approved the medicine aprocitentan (Jeraygo) to treat hypertension in adults whose blood pressure cannot ...
Posted by Michael Wonder on 17 Jan 2025
Seladelpar approved to treat adult patients in the UK with liver illness
16 January 2025 - As with any medicine, the MHRA will keep the safety and effectiveness of seladelpar under close review. ...
Posted by Michael Wonder on 11 Dec 2024
Delgocitinib approved to treat adult patients with moderate to severe chronic hand eczema
10 December 2024 - The MHRA has approved the medicine delgocitinib (Anzupgo) to treat moderate to severe chronic hand eczema in ...
Posted by Michael Wonder on 11 Oct 2024
MHRA approves Comirnaty KP.2 COVID-19 vaccine for adults
10 October 2024 - The MHRA has today approved an adapted Pfizer/BioNTech COVID-19 vaccine (Comirnaty) that targets the KP.2 COVID-19 sub-variant ...
Posted by Michael Wonder on 28 Sep 2024
MHRA approves first medicine for rare immune disease APDS
27 September 2024 - The MHRA has on 25 September approved leniolisib phosphate (Joenja) to treat a rare immune disease known ...
Posted by Michael Wonder on 09 Sep 2024
Celltrion’s Stelara biosimilar secures UK approval
4 September 2024 - Celltrion said its Stelara (ustekinumab) biosimilar, Steqeyma, received marketing authorisation from the UK MHRA. ...
Posted by Michael Wonder on 15 Aug 2024
Zolbetuximab approved to treat adults with stomach or gastro-oesophageal junction cancer
14 August 2024 - A new targeted cancer treatment, given in combination with a standard chemotherapy, for adults with stomach (gastric) ...
Posted by Michael Wonder on 26 Jul 2024
MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults
23 July 2024 - Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those ...
Posted by Michael Wonder on 02 Mar 2024
MHRA grants first approval via the new International Recognition Procedure in 30 days
1 March 2024 - Launched in January 2024, IRP aims to further help bring life-saving new medicines to UK patients without ...
Posted by Michael Wonder on 22 Feb 2024
UK's MHRA revokes authorisation for Novartis' sickle cell drug
21 February 2024 - Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle ...